Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I trial
Posted: 11 June 2015 |
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy in cancer patients suffering from acute myeloid leukaemia (AML) or multiple myeloma (MM).
The NKG2D CAR T-cell is an autologous chimeric antigen receptor T lymphocyte (CAR T-cell) therapy constructed using the native sequence of natural killer cell (NK cell) receptors which, unlike traditional CAR technologies such as those targeting the CD19 antigen, has the potential to target a broad range of solid tumours and blood cancers by targeting ligands present on numerous types of cancer cells.
The first patient enrolled in Phase I dose escalation study suffers from AML. Following the infusion of the first dose of NKG2D CAR T-cell, no safety issues were reported. This marks an important step in demonstrating the safety of NKG2D CAR-T cell infusion at that dose and triggers the enrollment of the next two patients in the first dose cohort.
Full readout from the Phase I trial of NKG2D CAR-T cell infusion is expected in mid-2016
Dr. Christian Homsy, CEO of Celyad, commented, “At 30 days post NKG2D CAR-T cell infusion for this first patient, no safety issues were reported. This is a great milestone in validating our new CAR T-cell platform. We look forward to recruiting of the remaining patients in this first dose cohort.”
The full data readout from the Phase I trial is expected in mid-2016. The trial is designed to assess the safety and feasibility of NKG2D CAR T-cell as primary endpoints, with secondary endpoints including clinical efficacy.
